Preliminary clinical trials harnessing the immune system of cancer patients to combat disease have shown to have impressive efficacy. Immune cells isolated from a patient are genetically altered to allow for improved detection of cancerous cells and subsequently re-introduced into the patient. Yet despite its promise, rapid and cost-effective manufacturing of this therapy remains a barrier to widespread adoption. This collaboration consisting of Drs. Shih and McComb, Haddad/Roy laboratories along with DropGenie will refine a lab-on-a-chip approach in which several laboratory operations have been integrated onto a single handheld device, thus allowing for automated liquid handling and optimization of experimental conditions specific to the genetic engineering of T cells. Streamlining the process will reduce costs and improve accessibility of the therapy for cancer patients while automation will improve standardization and reproducibility.